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Abstract MECP2 (methyl CpG binding protein 2) duplica-
tion causes syndromic intellectual disability. Patients often
suffer from life-threatening infections, suggesting an addition-
al immunodeficiency. We describe for the first time the
detailed infectious and immunological phenotype of MECP2
duplication syndrome. 17/27 analyzed patients suffered from
pneumonia, 5/27 from at least one episode of sepsis. Encap-
sulated bacteria (S.pneumoniae,H.influenzae) were frequently
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isolated. T-cell immunity showed no gross abnormalities
in 14/14 patients and IFNy-secretion upon ConA-
stimulation was not decreased in 6/7 patients. In 6/21
patients IgG2-deficiency was detected – in 4/21 patients
accompanied by IgA-deficiency, 10/21 patients showed
low antibody titers against pneumococci. Supra-normal
IgG1-levels were detected in 11/21 patients and supra-
normal IgG3-levels were seen in 8/21 patients – in 6 of
the patients as combined elevation of IgG1 and IgG3.
Three of the four patients with IgA/IgG2-deficiency de-
veloped multiple severe infections. Upon infections pro-
nounced acute-phase responses were common: 7/10 pa-
tients showed CRP values above 200 mg/l. Our data for
the first time show systematically that increased suscep-
tibility to infections in MECP2 duplication syndrome is
associated with IgA/IgG2-deficiency, low antibody titers
against pneumococci and elevated acute-phase re-
sponses. So patients with MECP2 duplication syndrome
and low IgA/IgG2 may benefit from prophylactic substi-
tution of sIgA and IgG.
Keywords Xq28-duplication syndrome . methyl CpG
binding protein 2 (MECP2) .MECP2 duplication syndrome .
primary immunodeficiency . intellectual disability . humoral
immunodeficiency
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Introduction
MECP2 duplication on chromosome Xq28 (#300260) causes
a severe form of X-linked intellectual disability (XLID). It was
first clinically described as Lubs syndrome, the underlying
genetic condition was identified in 2005 [1–3]. Up to now
more than 200 patients have been described [1–50]. The exact
prevalence ofMECP2 duplication syndrome is still unknown,
but in synopsis of different screening attempts it is estimated
thatMECP2 duplication syndromemay explain ~1% of cases
of severe XLID [51]. The core phenotype ofMECP2 duplica-
tion syndrome includes infantile hypotonia, mild dysmorphic
features, developmental delay/severe to profound intellectual
disabilty and absent to minimal speech [51]. Spasticity, ataxia
and autism are facultative clinical signs that occur in different
combinations and to different degrees. Since the description of
the first individuals it became evident that besides the striking
neurological phenotype patients with MECP2 duplication
syndrome are at increased risk for severe infections. About
70–75 % of the affected individuals are reported to develop
recurrent infections, especially of the respiratory tract. Respi-
ratory infections are the main cause of early death reported
among the population [51, 52]. However a detailed descrip-
tion of the infectious phenotype and an investigation of the
immunological phenotype based on a large cohort has been
missing to date.
Suspecting an immune dysfunction in patients with
MECP2 duplication syndrome we assessed the infectious
and immunological phenotype of a cohort of 30 patients. We
here provide for the first time a detailed description of the type
of infections, the pathogens isolated and the core cellular and
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humoral immunological phenotype in patients with MECP2
duplication syndrome.
Materials and Methods
Patients The current study was conducted in accordance with
the Helsinki Declaration, with informed consent obtained from
each patient or the patient’s family. Samples from the patients
were used in this study with approval from the local ethics
committee of the Charité (approval # EA2/063/12). All patients
enrolled in this study show a genetically confirmed duplication
of at leastMECP2 and IRAK1. The diagnostics were performed
prior to this study and the results were submitted to us by the
performing laboratories or geneticists. In patients P1, P2, P8, P9,
P10, P11, P12, P13, P14, P17, P19, P20, P21, P25, P27, P28,
P29 and P30 the duplication had been detected by use of array-
CGH thus revealing the actual size of the duplication on Xq28.
In Patient P15 quantitative PCR had been performed and in
patients P3, P4, P5, P6, P7, P18, P23, P24 and P26 Multiplex-
ligation probe amplification was used for the diagnosis of
MECP2 duplication and single neighbouring genes, e.g.,
IRAK1. So in patients P15, P3, P4, P5, P6, P7 and P18, P23,
P24 and P26 the actual size of the duplication is unknown. The
following patients have been described previously: P1, P2 in
Bartsch et al. [21], P3, P4, P5, P6, P7 in Echenne et al. [18], P8
in Budisteanu et al. [31], P9 in Jezela-Stanek et al. [28], P10 in
Mayo et al. [32], P12 in Grasshoff et al. [30], P13 in Bauters
et al. [9], P15 inMeins et al. [2], P17 inMadrigal et al. [8], P20,
P21 in Xu et al. [43], and P22, P27 in Vignoli et al. [40]. For
detailed molecular analyses of these patients see the corre-
sponding publications. Patients P11, P14, P16, P18, P19,
P23, P24, P25, P26, P28, P29 and P30 have not been published
before. For molecular characterization of these patients see
supplementary table 1.
Blood Samples of the Patients Venous punctures were per-
formed in parallel to routine blood tests. The blood samples
were sent to our laboratory to ensure that all patients’ samples
were analyzed with the same methods and with the same lab-
oratory equipment.
Assessment of the Infectious Phenotype A detailed question-
naire on the clinical phenotype was completed by the physicians
caring for the patients with MECP2 duplication syndrome and
sent to two of the authors (MB and HVB) for thorough review.
Assessment of Immunoglobulin Levels and Antibody Titers
Against Tetanus Toxoid and Pneumococci Total immunoglob-
ulin levels and immunoglobulin subclasses of all patients’ sam-
ples in our cohort weremeasured by ECLIA on a COBAS 6000
(Roche, Switzerland) in our laboratory. Antigen-specific IgG
antibodies against Tetanus-Toxoid and PCP as well as anti-
PCP-IgG2 of all patients’ samples in our cohort were measured
by ELISA according to manufacturer’s protocols (MK013,
MK012 and MK010, The Binding Site) in our laboratory.
Assessment of Lymphocyte Subsets Lymphocyte subsets of pa-
tients’ EDTA-blood were stained with fluorescence-labelled
monoclonal antibodies against CD14 (RMO52), CD56 (N901),
CD16 (3G8), CD4 (SFCI12T4D11), CD19 (J3-119), CD8
(SFCI21Thy2D3), CD3 (UCH-T1), CD45 (J33), CD45R0
(UCHL1), TCRαβ (IP26A), TCRγδ (IMMU510) and
CD45RA (2H4LDH11LDB9) (all Beckman Coulter, USA) for
15 min at room temperature and were measured and analyzed
after erythrocyte lysis (Versa-Lyse, Beckman Coulter) on a
NAVIOS-FACS (Beckman Coulter, USA) in our laboratory.
Lymphocyte Proliferation Assay Lymphocyte proliferative re-
sponses were tested according to standard protocols in
heparinised whole blood and were stimulated with phytohe-
magglutinin (PHA, Sigma-Aldrich, L1668), plate bound anti-
CD3 (3, 10, and 30 μg/ml; clone HIT3a, Becton Dicinson),
Pokeweed-Mitogen (PWM, 1, 5, and 15 μg/ml, Sigma-Al-
drich, L-9379), IL-2 (20 ng/ml, #200-02, PeproTech, Rocky
Hill/NJ, USA) and Staphylococcus aureus Cowan-1 strain
(SAC, Pansorbin, 1:1000, 1:10,000, Merck, Darmstadt, Ger-
many) for 72 h and with Tetanus-Toxoid RT50 (40, 20, and 10
Lf/ml, Staten Serum Inst. Copenhagen), Candida albicans an-
tigen (0.025, 0.25, and 2.5 μg/ml; CAN001-P; Biologo,
Kronshagen, Germany) and Diphtheria-Toxoid (20 LF/ml,
Chiron-Behring) for 120 h. After pulsing with 1 μCi [3H]-
thymidine per well during the last 12 h incorporated [3H]-
thymidine was measured on a β-scintillation counter
(MicroBeta 1450 TriLux, PerkinElmer).
Assessment of IFNγ After Stimulation with ConcanavalinA
(ConA) Heparinised bloodwas stimulated 1:5 diluted in RPMI
with 50 μg/ ml ConA (Sigma-Aldrich, #7246) and IFNy was
assessed by Th1/Th2-cytokine detection kit (Becton Dicinson
Biosciences, #550749) according to the manufacturers proto-
col. Measurement was performed on a FACS-Navios
(Beckman Coulter). For analysis FCAP-Array-Software (Soft
Flow Hungary) was used. The normal range of IFNy-secretion
upon activation with ConA after 4 h of activation was assessed
based on the activation of 50 healthy donors (25 male and 25
female). The normal range of IFNy-secretion upon activation
with ConA after 24 h of activation was assessed based on the
activation of 10 healthy male donors.
Results
Cohort, Genotypes and Infectious Phenotype 30 patients with
MECP2 duplication syndrome from Germany, France, Italy,
J Clin Immunol
Poland, Romania, Spain, The Netherlands, Belgium, USA
and China were enrolled in the study (28 male patients and
two female patients). All patients showed a duplication of
MECP2 and neighbouring IRAK1 (Fig. 1). Patients’ age
ranged from 3 to 48 years. We had access to the history of
27 of the 30 patients with 343 cumulative patient-years. The
occurrence of infections varied in our cohort of patients: In 9/
27 patients (including the two girls) no severe infections were
reported at all. 18/27 patients developed at least one severe
infection requiring intravenous antibiotic treatment. Pneumo-
nia occurred in 17/27 patients. Regarding the type of pneumo-
nia, complete assessment was possible in patient P14 and in
th is pa t ien t a l l pneumonias were X-ray-proven
bronchopneumoniae. 5/27 patients developed at least one ep-
isode of sepsis. Urinary tract infections were reported in 6/27
patients. Recurrent fever of unknown origin occurred in three
patients. No meningitis was diagnosed in our cohort. The fre-
quency of severe infections also varied with a maximum of 27
episodes requiring intravenous antibiotic treatment since birth
in a 16-year old boy (P1). Two patients died of pneumonia
during the course of the study (Table 1).
Of the 25 different pathogens detected in the patients, the
majority were bacteria with 84%. Only 3 viruses (12 %) and 1
fungus (4 %) were among the 25 pathogens. Of the 21 differ-
ent bacteria, 7 bacteria were Gram-positive (33 %) and 14
bacteria were Gram-negative (66 %). Thirteen of the 21 iso-
lated bacteria (61.9 %) are capable of building a capsule
(A.hydrophila [53], B.fragilis [54–56], E.coli [57],
H.influenzae [57], K.oxytoca [58], K.pneumonia [59],
P.mirabilis [60], P.aeruginosa [59, 61], S.aureus [62–65],
S.epidermidis [66, 67], S.agalactiae [57], Streptococcus
group A [68–70], S.pneumoniae [57, 64]).
Pathogens were isolated in pharyngeal swab, sputum, bron-
choalveolar lavage, bronchial secretion/aspirate, tracheal se-
cretion, ear swab, urine, stool, peritoneal liquid and blood.
When considering the isolation of pathogens in these biolog-
ical materials altogether, the pathogens isolated in most pa-
tientswere S.pneumoniae (5/27) andH.influenzae (5/27) - both
are typical encapsulated bacteria [64]. In 4/27 patients E. coli,
in 4/27 C.albicans, in 3/27 patients S.aureus, in 3/27
P.aeruginosa, in 2/27 P.mirabilis and in 2/27 Streptococcus
group A were isolated. S.agalactiae, Streptococcus group C,
Streptococcus group F, S.epidermidis, K.pneumonia,
K.oxytoca, M. tuberculosis, O.anthropi, A.hydrophila,
C.freundii, B.fragilis, S.enteritidis, S.marcescens and
S.plymuthica were each detected in one patient. Influenza A,
Respiratory-Syncytial-Virus and Rhinovirus were also each
isolated in only one patient (Fig. 2a).
When considering only the isolates in biological material
of the respiratory tract, the pathogens isolated in most patients
were H. influenzae (4/27) and C.albicans (4/27) followed by
S.pneumoniae (3/27) (Fig. 2a). The spectrum of pathogens
isolated in blood included S.pneumoniae, H.influenzae,
S.aureus, S.epidermidis and C.albicans, each only isolated
in one patient (Fig. 2b). Pathogens isolated in urine were
P.mirabilis (in 2/27 patients), E.coli (in 1/27 patients) and
S.pneumoniae (in 1/27 patients) (Fig. 2b). Neither infec-
tions by Pneumocystis jirovecii, nor invasive infections by
Fig. 1 Size of duplications in
MbP on chromosome Xq28.
The x-axis depicts positions on
chromosome Xq28 between 151
and 155 Mbp. Red bars indicate
duplicated segments, purple bars
indicate triplicated segments in
the individual patients. Positions
on the X chromosome are based
on the UCSC genome browser
build hg18. (* Duplication of
patient P29 extends the depicted
area on Xq28 to the left side until
position 147.384.720 bp)
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mycobacteria or S.enteritidis were observed. In summary
patients with MECP2 duplication syndrome show in-
creased susceptibility for pneumonia and sepsis caused
by bacteria that are mainly capable of building a capsule
(Fig. 2 and supplementary table 2).
Cellular and Humoral Immunological Phenotype Peripheral
blood smears of 21 patients showed values of total white
blood cells that were elevated in two patients (P9, P30).
Monocytes were slightly elevated in patient P9 and P22.
Neutrophilic granulocytes were increased in patient P9 and
P15, and reduced in patient P14. Eosinophilic and baso-
philic granulocytes were within normal ranges (supplemen-
tary figure 1). More detailed immunophenotyping of lym-
phocytes from 14 patients revealed numbers of total T
(CD3+) lymphocytes that were elevated in 1/14 patient.
CD4+ T-cells were above age-dependent reference value
in 1/14 (different) patient. Absolute numbers of CD8+ T-
cells were elevated in 1/14 further patient. In 5 of 14
patients tested naïve CD4+ T-cells (CD4+CD45RA+) were
elevated, while memory CD4+ T-cells (CD4+CD45RO+)
were reduced. B-cells (CD19+) were reduced in 3 of the 14
patients tested and NK-cells (CD16+CD56+CD3-) were below
age-dependent reference value in 1 of the 14 patients tested
(supplementary table 3A and supplementary table 3B).
Lymphocyte proliferation upon stimulation with mitogens
(PHA, PWM) was normal in 13 patients tested. Stimulation
with IL-2 showed attenuated responses in 2/13 patients and
stimulation with anti-CD3 revealed a lymphocyte response
below reference value in 1/13 patients. When stimulating
cells of the 13 patients with SAC, 3 patients showed re-
duced lymphocyte response. Attenuated lymphocyte prolif-
eration was also observed upon stimulation with candida-
antigen (3 of 13 patients tested), diphtheria-antigen (5 of 13
patients tested) and tetanus toxoid antigen (2 of 13 patients
tested) (supplementary table 4).
We tested IFNy-secretion upon stimulation with ConA for
24 h in whole blood of 7 patients. We observed a normal
production of IFNy in blood that was stimulated soon after
the blood withdrawal (n=1). In blood that had travelled, 4
patients showed an IFNy-level after stimulation that was with-
in the reference values of healthy controls. The IFNy-level of
one patient was above the reference value and the IFNy-level
of one patient was below reference values. So in total in 6/7
patients tested IFNy-production upon stimulation with ConA
was not impaired (Fig. 3). In summary lymphocyte subsets
and lymphocyte proliferation assays show no gross abnormal-
ities and IFNy-production upon stimulation with ConA seems
to be normal.
Of 30 patients enrolled we could assess immunoglobulin
levels (IgG, IgA and IgM), and levels of IgG subclasses
(IgG1 – IgG4) and specific antibodies against tetanus and pneu-
mococci in 21 patients. This revealed six patients with IgG2-T
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deficiency – four of them with an additional IgA-deficiency.
One of the four patients with IgA/IgG2-deficiency had global-
ized low levels also for IgG, IgG1, IgG3, IgG4 and IgM. Addi-
tionally IgG2 was in low normal range in 3 further patients.
IgG4 was below reference values in 4 patients, all of which also
had IgG2-deficiency. IgG1 was above age-dependent reference
values in 11/21 and IgG3 was above age-dependent reference
values in 8/21 patients; 6/21 patients showed supra-normal
values for IgG1 and IgG3 (Fig. 4a–g), IgG2-antibodies against
S.pneumoniae were below normal values in 4 patients, in
whom also IgG2 was low. Additionally S.pneumoniae IgG2-
antibodies were in the lower range of normal in 6 further pa-
tients. So in total 10/21 patients showed low antibody titers
against pneumococci (Fig. 5). Of the 21 patients in whom we
assessed the levels of S.pneumoniae IgG2-antibodies, 8 patients
had received vaccination against pneumococci, 8 patients had
not received vaccination and in five patients information on
vaccination status was not available. Interestingly
S.pneumoniae IgG2-antibodies were low even in the patients
with vaccination against pneumococci (Fig. 5). Both pneumo-
coccal polysaccharide vaccines and pneumococcal conjugate
vaccines have been used in the 8 patients with pneumococcal
vaccination and 7 of the 8 patients have received several pneu-
mococcal vaccinations. The period between last vaccination
and assessment of aPCP-IgG2 ranged from 1 month up to
7 years and 6 month. It is noteworthy that even in the patient
with the short interval of 1 month between last vaccination and
ascertainment of antibody titers no appropriate antibody pro-
duction against S. pneumoniae was determined after three vac-
cinations (Table 2). In contrast to this rather common
impairement of IgG2 formation against pneumococci IgG-
antibodies against Tetanus-Toxoid were below age-dependent
reference values in only 2/21 patients and low in normal range
in 2 further patients, so normal in 19/21 patients (supplementary
figure 2). In summary 6/21 patients show IgG2-deficiency –
four of them with an additional IgA-deficiency - and half of
the patients (10/21) show antibodies against pneumococci ei-
ther below normal range or in the low range of normal.
Fig. 2 Pathogens isolated in patients with MECP2 duplication syndrome and number of patients each pathogen was detected in. a. All biological
material and material of the respiratory tract b. Blood and Urine
Fig. 3 Interferon-y secretion in whole blood upon stimulation with
ConA. (Normal ranges are depicted as dotted lines)
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Acute-Phase Responses As infections in patients withMECP2
duplication syndrome have not only been reported for their
high frequency but also for the severity of the single infectious
episode we systematically assessed acute-phase responses in
these patients. Data on acute-phase responses was available
for 10 patients. 7/10 patients experienced non-invasive infec-
tions with maximal CRP values above 200 mg/l. In 4/10 pa-
tients CRP values above 300 mg/l were reported during non
invasive infections. Only one patient (P16) showed no elevated
CRP values upon non-invasive infections. The mean value of
all reported maximal CRP values during non-invasive infec-
tions of all patients was 157,58 mg/l (Fig. 6a). The maximal
temperature measured during non-invasive infections ranged
from 38.5 to 41.6 °C and the mean value measured during
non-invasive infections of all patients was 39.75 °C (Fig. 6b).
2/10 patients experienced non-invasive infections with leuco-
cyte counts above 30/nl and 8/10 patients showed leucocyte
counts above 20/nl during single infectious episodes. Mean of
all reportedmaximal leucocyte values was 15.69/nl (Fig. 6c). 5/
10 patients showed a neutrophil count above 15/nl during a
non-invasive infection. The mean value of the maximal neutro-
phil count for all patients was 10.51/nl (Fig. 6d). Taken together
these data indicate a strong acute-phase response in patients
with MECP2 duplication syndrome.
Discussion
The duplication of MECP2 on chromosome Xq28 leads to a
rather common syndromic form of XLID (estimated ~1 % of
x-linked patients). Besides the neurological phenotype it was
soon noted that many of the patients suffer from recurrent
infections [51, 52]. We here describe for the first time, system-
atically the infectious and immunological phenotype of
MECP2 duplication syndrome based on data derived from a
standardized study-questionnaire filled out by the physicians
together with the parents of 30 patients. Our findings show
that patients with MECP2 duplication syndrome are at an
increased risk for infections by bacteria that are able to
build capsules (61.9 % of isolated pathogens); in particular
for infections by S.pneumoniae and H.influenzae. In our
cohort we have not observed increased susceptibility to
mycobacteria, pneumocystis spp, fungi and viruses. We
Fig. 4 Humoral immunological phenotype of patients withMECP2 duplication syndrome. a. IgG2 levels. b. IgG1 levels. c. IgG3 levels. d. IgG levels. e.
IgA levels. f. IgM levels. g. IgG4 levels. (Normal ranges are depicted as dotted lines)
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could not identify a correlation between the size of the
duplication (genotype) and the infectious or immunological
phenotype. The predominance of respiratory and severe inva-
sive infections caused by bacteria that are able to build capsules,
suggested an impairment of humoral immunology.
IgG2-deficiency was detected in 6/21 analyzed patients - in
4/6 patients accompanied by IgA-deficiency, while 15 out of
21 analyzed patients showed no IgG2 or IgA deficiency. IgG2-
deficiency in the 6/21 patients and low antibody titers against
pneumococci in 10/21 patients suggest that among patients
with MECP2 duplication humoral impairement is more com-
mon than in the normal population. 5/6 patients with IgG2-
deficiency also developed severe infections. As 3/4 individ-
uals with combined IgA/IgG2-deficiency additionally suffered
from a very high frequency of infections and developed the
most severe infectious phenotype in our cohort there seems at
least an association of IgA-/IgG2-deficiency with severe infec-
tions. In line with this hypothesis only 2/15 patients without
IgA or IgG2 deficiency developed recurrent severe infections
comparable to the phenotype observed in the patients with
IgA/IgG2-deficiency. One of them showed low IgG2-anti-
bodies against pneumococci even after vaccination indicating
an inability to mount an appropriate antibody production al-
though global levels of immunoglobulins are normal in this
patient. The other patient (P9) with a severe infectious pheno-
type despite having an IgA-/IgG2-deficiency showedmassively
elevated IgG (32 g/l). Given the fact that this patient has a
persistently raised leucocyte count, it seems plausible that he
additionally suffers from an unknown chronic inflammatory
process. 7 of the 15 patients without IgA or IgG2 deficiency
Fig. 5 Humoral immunological phenotype of patients with MECP2
duplication syndrome. a. IgG2 levels against S. pneumoniae in all
patients tested. b. IgG2 levels against S. pneumoniae of patients with
vaccination. c. IgG2 levels against S. pneumoniae of patients without
vaccination d. IgG2 levels against S. pneumoniae of patients with
unknown vaccination status (Normal ranges are depicted as dotted lines)
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developed few infections and 2 of the 15 patients developed no
infections. In 4 of the 15 patients without IgA or IgG2 deficien-
cy the severity of the infectious phenotype could not be
assessed as the patient was either still at young age or because
the history could not be completed appropriately. The single
patient who has to date not developed severe infections despite
Table 2 Pneumococcal
vaccination in patients with
MECP2 duplication syndrome
Type of vaccine, number of
vaccinations, time between last
vaccination and assessment of
aPCP IgG2, age at last
vaccination
PCV polysaccharide conjugated
vaccine, PPV23 23-valent
pneumococcal polysaccharide
vaccine
Patient Type of vaccine Number of
vaccinations
Time between last vaccination
and assessment of aPCP IgG2
Age at last vaccination
P16 PCV 5 3 months 3 years, 4 months
P17 PCV 2 7 years, 7 months 1 year, 8 months
P23 PCV 3 6 years, 10 months 10 months
P28 PCV 4 3 years, 4 months 1 year, 1 month
P29 PCV 4 5 years, 9 months 2 years
P1 PPV23 3 1 month 11 years, 1 month
P14 PPV23 2 1 year, 7 months 12 years, 11 months
P18 PPV23 1 7 years, 6 months 2 years, 3 months
Fig. 6 Acute phase responses in patients with MECP2 duplication
syndrome. a. Maximal CRP-level during non-invasve infections. Upper
reference value is 5 mg/l b. Maximal temperature during non-invasive
infections c.Maximal leucocyte count during non-invasive infections. d.
Maximal neutrophil count during non-invasive infections
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IgA/IgG2-deficiency is female. So in MECP2 duplication syn-
drome not all patients develop humoral immunodeficiency but
severe infections with potentially encapsulated bacteria are, at
least in male patients, strongly associated with a lack of IgA
and IgG2.
We further investigated whether patients with MECP2 du-
plication syndrome showed stronger acute phase responses,
which we could confirm in 7/10 patients in terms of elevated
CRP values above 200 mg/l during non-invasive infections,
mainly pneumoniae. This observation raises the question if the
genetic alterations in patients with MECP2 duplication syn-
drome lead to a hyper-inflammatory immune response. Be-
cause all patients show a duplication on Xq28 that includes
MECP2 and neighbouring IRAK1 and given the fact that these
two genes were assumed to be the minimal critical region
leading to the phenotype of MECP2 duplication syndrome
until recently [15, 17, 51], it seems plausible to hypothesize
a role of IRAK1 in the pathogenesis of strong acute-phase
responses. IRAK1 encodes for a protein in the TLR/IL1R-
signalling pathway and it could be assumed that its overex-
pression leads to stronger or constantly triggered NFκB-
mediated pro-inflammatory signalling and to a hyper-
inflammatory immune response. In our opinion recently pub-
lished results suggesting normal TLR-mediated signalling in
PBMCs of patients with MECP2/IRAK1 duplication do not
sufficiently falsify this hypothesis as these experiments were
performed in PBMCs (without granulocytes) and as it remains
unclear whether LPS-stimulation was performed with or with-
out serum [44]. So it seems at least possible that the previously
described similar production of cytokines upon activation
with TLR-agonists in patients and controls in these experi-
ments is due to the insufficient stimulation of cells or a lack
of stimulation of granulocytes or both. So to date it remains an
open question whether the duplication of IRAK1 renders pa-
tients with MECP2 duplication prone to strong inflammatory
responses.
It has been published thatMECP2 duplication causes a lack
of TH1-differentiation, elevated levels of CD4+CD45RA+
naïve/ lowered levels of CD4+CD45R0+ memory T-cells
and impaired IFNγ-secretion by T-cells inmice and in patients
with MECP2 duplication. It was concluded that this lack of
TH1 differentiation/ IFNγ-secretion is the major cause for the
increased susceptibility for infections in patients withMECP2
duplication [44]. These observations are partially in line with
ours. Also in our cohort 5/14 patients showed elevated levels
of CD4+CD45RA+ naïve/ lowered levels of CD4+CD45R0+
memory T-cells. The observed ratio of CD4+CD45RA naïve
versus CD4+CD45R0+ memory T-cells in our cohort is >1 in
11/14 patients and < 1 in 3/14 patients. However our data do
not fully confirm the hypothesis of an impaired IFNγ-
secretion as sufficient explanation for the increased suscepti-
bility to infections: 1. Upon ConA-stimulation we observed a
normal IFNγ-production in 5/7 patients, an even stronger
IFNγ-production in one patient and only a slightly impaired
IFNγ-production in one patient compared to healthy controls
(Fig. 3); 2. If the observed reduction of IFNγ-secretion in
patients with MECP2 duplication was causative for severe
infections one would expect disseminated and/or invasive in-
fections with atypical mycobacteria and S.enteritidis as de-
scribed for molecular precisely–defined partial and complete
defects in at least 9 genes leading to the impairment of IFNγ-
receptor signalling or IFNγ-secretion [71–74]; 3. Conversely
during a total of 343 patient years in our study only one patient
(P9) developed a single, non-complicated infection by
M.tuberculosis, which remained restricted to the lung and
was successfully treated by standard therapy. In a patient with
a strongly relevant impairement of IFNγ-secretion an infec-
tion with M.tuberculosis would have taken a severe course
[71–74]. Interestingly however 13/21 patients developed ei-
ther supra-normal values of IgG1 of IgG3 or of both, IgG1 and
IgG3. This observation suggests a direct or indirect effect of
MECP2 duplication on the expression of IgG3 and IgG1 at the
γ3/γ1 locus and of IgA, IgG2 and IgG4 at the α1/γ2/γ4 locus.
It has been shown that IFNy stimulates the expression of the
IgG2a-isotype and inhibits the production of IgG3, IgG1, IgG2b
and IgE in mice [75]. So a deficiency in IFNy-secretion may
lead to alterations of immunoglobulin levels in humans with
MECP2 duplication although the role of IFNy in the regula-
tion of IgG3 is controversial [76, 77]. We did not observe a
generally impaired IFNy secretion in our cohort. However
previously published results on irregularities in IFNy secretion
should be taken into account as being responsible for altered
immunoglobulin levels in patients with MECP2 duplication
syndrome [44].
Besides the classical encapsulated bacteria S. pneumoniae
and H.influenzae several other bacteriae were also isolated in
the patients of our cohort, that are indeed able to build cap-
sules but are not clearly linked to capsule-related virulence. So
it remains unclear if humoral immunodeficiency is causative
also for infections by these facultative-encapsulated patho-
gens or if additional cellular immune deficits also account
for the broad spectrum of observed pathogens in patients with
MECP2 duplication syndrome.
In summary we here show for the first time systematically
that patients with MECP2 duplication syndrome are at in-
creased risk for in particular non-invasive but also for invasive
infections with potentially encapsulated bacteria, that this in-
creased susceptibility to infections may be associated with
IgG2-subclass deficiency/ low titers against pneumococci
and elevated acute-phase responses, while the precise role of
T-cell immunity and in particular the extent of impaired IFNγ-
secretion and its role for the observed infectious phenotype is
still to be defined. Based on our observation we hypothesize a
multifactorial pathogenesis of infections in patients with
MECP2 duplication syndrome: Pulmonary infections may
be triggered by frequent aspirations due to the severe
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neurological phenotype and favoured due to humoral immu-
nodeficiency. The observed alterations in the IgG subclass
composition (high IgG1/IgG3 and low IgA/IgG2/IgG4) may
be caused directly by interaction of MECP2 with the respec-
tive loci or indirectly by spatially impaired IFNγ-secretion.
An increased susceptibility to hyper-inflammation either
caused by IRAK1 duplication or other direct or indirect effects
ofMECP2 duplicationmay aggravate infections. Based on the
compiled immunological and infectious findings we recom-
mend to vaccinate patients with MECP2 duplication against
pneumococci and to evaluate post-vaccination titers. If post-
vaccination titers are not sufficient, several boosts might be
required. In patients with MECP2 duplication syndrome,
suffering from recurrent infections and with an IgG2-sub-
class deficiency and/or low post-vaccination titers against
pneumococci prophylactic substitution of IgG seems a
plausible strategy to prevent infections – eventually in
combination with the use of prophylactic antibiotics.
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